This article argues that significant, often overlooked, progress is being made in the global fight against cancer, countering common perceptions of a losing battle. Using the personal story of Jon Gluck, who has survived multiple myeloma for over two decades thanks to advanced treatments, the piece highlights a substantial decline in age-adjusted cancer death rates since 1991, equating to millions of lives saved. It attributes this success to three "revolutions": effective risk reduction (e.g., anti-smoking campaigns, HPV vaccine), advancements in early detection and screening (e.g., increased colonoscopies, AI/blood tests), and groundbreaking new treatments like CAR-T therapy. While acknowledging ongoing challenges, such as rising gastrointestinal cancers in younger demographics and the chronic nature of some diseases, the article presents an overall optimistic outlook on the future of cancer care.
Summary of the Main Transcript:
~0:00 Introduction & Overlooked Progress: The article challenges the perception that the "war on cancer" is being lost, asserting that quiet revolutions have prevented millions of cancer deaths. It introduces Jon Gluck, who was diagnosed with severe multiple myeloma in 2003 and given 18 months to live but is still in remission over 20 years later, highlighting real-world success against the odds.
~2:30 Declining Cancer Death Rates: The age-adjusted cancer death rate in the US has declined by about a third since 1991, leading to over 4 million fewer cancer deaths. This improvement extends beyond smoking-related cancers to non-lung cancers (stomach, colon) and childhood cancers, which have seen a sixfold decline since 1950. For example, five-year survival rates for acute lymphoblastic leukemia in children rose from ~10% in the 1960s to >90% today.
~4:00 Overall Survival Improvements: The five-year survival rate for all cancers has increased from 49% in the mid-1970s to 69% in 2019. Specifically for Jon Gluck's multiple myeloma, the five-year survival rate has nearly doubled from 34% (around his diagnosis) to 62% today.
~4:15 Three Revolutions in Cancer Progress:
Risk Reduction: Anti-smoking policies are identified as the single biggest lifesaver. The HPV vaccine has also significantly reduced cervical cancer deaths in young women (e.g., a 62% drop in US women under 25 between 2013-2021).
Better and Earlier Screening: Early detection remains crucial for improved survival. A notable example is the one-third decline in late-stage colorectal cancer incidence in Americans over 50 (2000-2010), largely due to increased colonoscopy rates. Future screening methods aim to detect cancer before symptoms using AI and blood-based tests.
Frontier Treatments: Advances in drugs like lenalidomide and bortezomib have doubled median myeloma survival. Most promising is CAR-T therapy, an immunotherapy that re-engineers a patient's T-cells to attack cancer. A study showed one-third of multiple myeloma patients facing hospice achieved no detectable cancer five years later after CAR-T, a treatment Jon Gluck himself benefited from in 2023.
~7:45 Remaining Challenges and "Welcome Uncertainty": Despite significant wins, challenges persist, such as the rising rates of gastrointestinal cancers among younger people. However, for many patients like Jon, the future now holds a "welcome uncertainty" β the ability to live with a controllable disease rather than facing a definite death sentence, a situation unimaginable two decades ago.
Summary of the Discussion:
The Hacker News discussion largely affirmed the article's premise of significant progress in cancer treatment, enriched by numerous personal anecdotes and expert insights, while also highlighting critical systemic challenges.
Personal Testimonies of Breakthroughs:
Many commenters shared personal stories (or those of family/friends) of surviving cancers that were once fatal, directly attributing their extended lives to modern treatments (e.g., MD Anderson's tailored treatments, R-CHOP, CAR-T therapy). One user's large tumors vanished within hours of targeted drug infusion.
Experiences detailed improvements in quality of life with newer treatments (e.g., 4 pills/day with weight gain as primary side effect vs. constant exhaustion from older treatments).
Nuances and Challenges of Progress:
While acknowledging statistical improvements, some felt "winning" was an overstatement, pointing out cancer's continued high death toll, the pain of treatment, and the chronic nature of some cancers.
A precision oncology professional argued that most patients (over 80%) still receive standard chemo/radio/surgery, and individualized biotech therapies remain largely for "select individuals with A LOT of money."
Concerns were raised about rising rates of gastrointestinal cancers among younger people, suggesting environmental factors like diet, plastics, PFAS, or obesity.
Prevention and Early Detection:
Many emphasized the importance of prevention (e.g., anti-smoking policies) and early detection, advocating for colonoscopies starting at age 45 due to increasing colorectal cancer rates in younger demographics.
Discussions included the pros and cons of less invasive home screening tests (FOBT, FIT-DNA) versus colonoscopies, with the latter's ability to remove polyps before they become cancerous being a key advantage.
A detailed comment highlighted societal shifts around 1990 (tobacco restrictions, Clean Air Act, EPA regulations) as primary drivers of the death rate decline, arguing that societal changes (like addressing sugar, weight gain) are more impactful than medical interventions alone.
Access to Care and Systemic Issues:
A recurring theme was the significant bottlenecks in accessing advanced medical care, particularly long wait times for CT/MRI scans and insurance approval processes, which can cause severe delays and added suffering.
Commenters described "broken" American medicine, where scheduling appointments is complex and access is often dependent on financial privilege, insurance, and proximity to specialized centers like MD Anderson.
Future Treatments and AI:
Discussions touched on cutting-edge treatments like CAR-T therapy being "mindbogglingly insane cyberpunk stuff" and the potential of ferroptosis as a new mechanism to kill metastases.
Interest was expressed in non-invasive treatments like Novocure's electric field helmet for Glioblastoma (though some were skeptical of the mechanism or noted potential self-selection bias for compliant patients).
The potential for AI/Machine Learning in spotting early cancers was highlighted, with generative AI speculated to help find "needles in haystacks" of research data.
Political and Funding Impacts:
A contentious sub-thread debated the impact of current US administration policies on cancer research funding, with some claiming massive cuts to NIH/NSF grants and a "decimated" biological research landscape, while others countered that the budget wasn't cut but rather not being spent, leading to a "crisis" in research capacity.
Other Diseases: One commenter expressed frustration that Type 1 Diabetes remains incurable, feeling humanity has "failed" diabetics despite technological progress, though others countered that T1D life expectancy is trending upwards.